AU2015333645B2 - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Download PDF

Info

Publication number
AU2015333645B2
AU2015333645B2 AU2015333645A AU2015333645A AU2015333645B2 AU 2015333645 B2 AU2015333645 B2 AU 2015333645B2 AU 2015333645 A AU2015333645 A AU 2015333645A AU 2015333645 A AU2015333645 A AU 2015333645A AU 2015333645 B2 AU2015333645 B2 AU 2015333645B2
Authority
AU
Australia
Prior art keywords
glucocorticoid
receptor antagonists
liver disease
fatty liver
disease treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015333645A
Other languages
English (en)
Other versions
AU2015333645A1 (en
Inventor
Joseph K. Belanoff
Hazel Hunt
Onno C. MEIJER
Jose VAN DEN HEUVEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of AU2015333645A1 publication Critical patent/AU2015333645A1/en
Application granted granted Critical
Publication of AU2015333645B2 publication Critical patent/AU2015333645B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015333645A 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Active AU2015333645B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US62/064,358 2014-10-15
US201462092041P 2014-12-15 2014-12-15
US62/092,041 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
AU2015333645A1 AU2015333645A1 (en) 2017-05-04
AU2015333645B2 true AU2015333645B2 (en) 2020-01-30

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015333645A Active AU2015333645B2 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Country Status (22)

Country Link
US (5) US10238659B2 (2)
EP (2) EP4353310A3 (2)
JP (1) JP6761410B2 (2)
KR (1) KR102435956B1 (2)
CN (2) CN107106562B (2)
AU (1) AU2015333645B2 (2)
BR (1) BR112017007860B1 (2)
CA (1) CA2964625C (2)
DK (1) DK3206692T3 (2)
ES (1) ES2978871T3 (2)
FI (1) FI3206692T3 (2)
IL (1) IL251729B (2)
MX (1) MX2017004943A (2)
NZ (1) NZ731060A (2)
PH (1) PH12017500710B1 (2)
PL (1) PL3206692T3 (2)
PT (1) PT3206692T (2)
RU (1) RU2718921C2 (2)
SG (1) SG11201703024VA (2)
UA (1) UA123537C2 (2)
WO (1) WO2016061195A1 (2)
ZA (1) ZA201702813B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
CA3102099C (en) 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
CA3182272A1 (en) * 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2021226258A1 (en) * 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
MX2023007403A (es) * 2020-12-21 2023-08-16 Corcept Therapeutics Inc Método de preparación de los moduladores del receptor de ciclohexilo de pirimidina glucocorticoides.
CA3217413A1 (en) * 2021-05-05 2022-11-10 Ada Lee Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation
EP4732836A1 (en) 2024-10-22 2026-04-29 Consejo Superior De Investigaciones Científicas Ag5 compound for use in the treatment of in fatty liver diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105838A2 (en) * 2002-06-14 2003-12-24 The University Of Edinburgh Metabolite
US20070066557A1 (en) * 2005-09-19 2007-03-22 Monia Brett P Modulation of glucocorticoid receptor expression
US20130072486A1 (en) * 2011-03-18 2013-03-21 Corcept Therapeutics, Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
EP1534273A4 (en) 2002-07-18 2007-08-22 Bristol Myers Squibb Co MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
WO2006124710A1 (en) 2005-05-18 2006-11-23 Merck & Co., Inc. D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008127591A2 (en) 2007-04-13 2008-10-23 Schering Corporation Pyrimidinedione derivatives and use thereof
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105838A2 (en) * 2002-06-14 2003-12-24 The University Of Edinburgh Metabolite
US20070066557A1 (en) * 2005-09-19 2007-03-22 Monia Brett P Modulation of glucocorticoid receptor expression
US20130072486A1 (en) * 2011-03-18 2013-03-21 Corcept Therapeutics, Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUNT, H.J. et al. "Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat" Bioorganic & Medicinal Chemistry Letters (2012) Vol.22 No.24, pages 7376 to 7380 *
RAY, N.C. et al. "Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators" Bioorganic & Medicinal Chemistry Letters (2007) Vol.17 No.17, pages 4901 to 4905 *
WADA, T. et al. Endocrinology (2010) Vol.151 No.5, pages 2040 to 2049 *

Also Published As

Publication number Publication date
JP6761410B2 (ja) 2020-09-23
CA2964625C (en) 2023-03-07
AU2015333645A1 (en) 2017-05-04
PL3206692T3 (pl) 2024-07-22
US20210085682A1 (en) 2021-03-25
CN111557942B (zh) 2023-10-03
CN111557942A (zh) 2020-08-21
KR20170066646A (ko) 2017-06-14
KR102435956B1 (ko) 2022-08-23
RU2718921C2 (ru) 2020-04-15
US10238659B2 (en) 2019-03-26
RU2017114596A (ru) 2018-11-15
US20230218621A1 (en) 2023-07-13
JP2017531013A (ja) 2017-10-19
PT3206692T (pt) 2024-04-30
IL251729B (en) 2020-03-31
IL251729A0 (en) 2017-06-29
BR112017007860A2 (pt) 2018-01-16
FI3206692T3 (fi) 2024-05-06
PH12017500710A1 (en) 2017-10-09
BR112017007860B1 (pt) 2023-03-07
EP3206692A4 (en) 2018-05-30
SG11201703024VA (en) 2017-05-30
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
UA123537C2 (uk) 2021-04-21
ES2978871T3 (es) 2024-09-23
CN107106562B (zh) 2020-08-18
EP4353310A3 (en) 2024-06-19
CA2964625A1 (en) 2016-04-21
US11590135B2 (en) 2023-02-28
DK3206692T3 (da) 2024-04-29
US12226417B2 (en) 2025-02-18
US20190151318A1 (en) 2019-05-23
MX2017004943A (es) 2017-07-19
EP3206692B1 (en) 2024-04-03
US20160106749A1 (en) 2016-04-21
ZA201702813B (en) 2019-05-29
WO2016061195A1 (en) 2016-04-21
EP4353310A2 (en) 2024-04-17
PH12017500710B1 (en) 2024-01-17
CN107106562A (zh) 2017-08-29
EP3206692A1 (en) 2017-08-23
RU2017114596A3 (2) 2019-05-08
NZ731060A (en) 2023-07-28

Similar Documents

Publication Publication Date Title
AU2015333645B2 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
EP3221463A4 (en) Biomarkers for fatty liver disease and methods using the same
EP3119393A4 (en) 5-substituted indazole-3-carboxamides and preparation and use thereof
EP3152419A4 (en) Mixer and doser cone assembly
EP3148729A4 (en) Hydride-coated microparticles and methods for making the same
SG11201609645YA (en) Device for connecting the structural elements of ribs and reticular structures
EP3265094A4 (en) Atherosclerosis imaging agents and methods of using the same
SG11201608217PA (en) Fatty acid composition and use thereof
EP3117827A4 (en) Composition for vagina and use of the composition
EP3191483A4 (en) Compounds as crth2 antagonist and uses thereof
EP3185873A4 (en) Pharmaceutical composition and methods
GB2530559B (en) Mixing bowl
EP3126378A4 (en) Cardiotonic steroid antagonists and related methods
EP3113774A4 (en) Compositions of grapiprant and methods for using the same
IL246944B (en) A process for the preparation of abiraterone acetate and its intermediates
IL247828A0 (en) Progesterone compounds
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
ZA201607353B (en) Bicyclic derivatives and pharmaceutical composition including the same
EP3166406A4 (en) Cytokine-chitosan bioconjugates and methods of using the same
EP3094172A4 (en) Animal claw shearing apparatuses and methods of using the same
EP3157543A4 (en) Compositions and methods for the diagnosis of systemic autoimmune disease
EP3132427A4 (en) Auger and sleeve
AU2015230999A1 (en) 5-substituted indazole-3-carboxamides and preparation and use thereof
GB201411741D0 (en) Mixing bowl stand
AU2014902457A0 (en) Chimeric antigen receptor and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)